Clinicians need to be mindful of the pneumonitis risk with anti–PD-1/PD-L1 agents and factors that may increase a patient’s risk (combination therapy, solid tumors [NSCLC, RCC], smoking, age), evaluating any new symptoms as treatment related. Here, CD274 is linked to pneumonitis.